Cambodian-language VISs
Out-of-date
The translations for some VISs on our website are from previously
published English-language versions that have since been updated.
Unfortunately, IAC is not always able to obtain translations as
updates are issued. Please ensure that your patients receive
information consistent with the current English-language version of
the following VISs.
You are encouraged
to distribute the up-to-date English-language
VIS at the
same time as the translation.
These translations do not
contain the following CDC updates:
- Information was added about MMRV vaccine, tied to the
March 14 MMWR, regarding increased risk of certain adverse events,
including febrile seizures, with MMRV when compared with MMR and
varicella vaccines given separately. Aside from two boxes containing
information about MMRV, both VISs are identical to the previous
editions.
- The new VISs should be used when MMRV is given; but the existing
stocks of the individual MMR and varicella VISs may be used when the
vaccines are given separately.
This translation does not contain the
following CDC updates:
- Section 1: The
answer has been rewritten by CDC.
- Section 2: There
are now 2 doses; the first dose is 12-15 months and the second
dose is 4-6 years.
- CDC added information
on MMRV.
- The URL for Vaccine
Adverse Event Reporting System (VAERS) has changed to www.vaers.hhs.gov
- The URL for the
National Vaccine Injury Compensation Programs has changed to
www.hrsa.gov/vaccincompensation
These translations do not contain the following
CDC updates:
- These translations do not contain the following CDC updates
- The main change is in Section 4, which now mentions Tdap.
- The NVICP and VAERS web addresses have also been updated
- The mortality rate for tetanus in Section 1 changed from 1 out of
10, to 2 out of 10 cases.
- The date changed to 5/17/07.
These translations do not contain the
following CDC updates:
- On July 18, the CDC posted an interim
VIS for hepatitis B. There are minor changes throughout, but the main
purpose of the update is to emphasize the birth dose for all children.
- A final version will be developed.
This translation does not contain the
following CDC updates:
- The CDC posted an updated interim PCV VIS on 12/9/08. The main
reason is to incorporate recent changes in recommendations for 2-4
year olds, but there are other changes throughout as well. There
are no changes in contraindications or adverse events, but to
prevent parents from getting confused about the differences in
indications (especially when the vaccine is administered to 2-4
year olds) it would be best for providers to start using the new
version right away. Existing stocks CAN still be used temporarily
if immediately switching to the new version is a problem.
- Information on
the projected 3-year duration of protection has been deleted
(it's likely much longer)
- An upper age limit "under
5 years" has been placed on vaccinating children over
the age of two years who are at increased risk of serious pneumococcal
disease.
- The website of
the Vaccine Adverse Event Reporting System has
been added.
- A new URL for the
National Vaccine Injury Compensation Program
has been added.
You will be linked to the CDC website,
to download the Smallpox pre-vaccination information packet, which
includes the Smallpox VIS.
Please
note: there are supplements that come with this VIS, but the
supplements have not been translated, just the VIS.
Thanks to
the Minnesota Department of Health and the California Department
of Health Services for their translations.This page was updated on
December 11, 2008 |
Immunization Action Coalition
IAC Home
